Which has better earnings and valuation, ACRV or ELDN?

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A Eledon Pharmaceuticals N/A N/A -$45.62M -$0.77 N/A

Is ACRV or ELDN more profitable?

Acrivon Therapeutics' return on equity of -64.43% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -64.43% -57.08% Eledon Pharmaceuticals N/A -116.97% -41.91%

Do analysts recommend ACRV or NLTX?

Acrivon Therapeutics currently has a consensus price target of $11.67, suggesting a potential upside of 495.24%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, ACRV or NLTX?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A

Is ACRV or NLTX more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -64.43% -57.08% Neoleukin Therapeutics N/A -37.22% -30.91%

Which has better earnings & valuation, ACRV or INDP?

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A

Is ACRV or INDP more profitable?

Acrivon Therapeutics' return on equity of -64.43% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -64.43% -57.08% Indaptus Therapeutics N/A -1,030.07% -299.69%

Acrivon Therapeutics (ACRV) Competitors

$1.96 0.00 (0.00%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$1.96 0.00 (0.00%)

As of 07/10/2026 07:08 PM Eastern

Compare

ACRV vs. ORGO, BCYC, ELDN, NLTX, and INDP

Should you buy Acrivon Therapeutics stock or one of its competitors? MarketBeat compares Acrivon Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acrivon Therapeutics include Organogenesis (ORGO), Bicycle Therapeutics (BCYC), Eledon Pharmaceuticals (ELDN), Neoleukin Therapeutics (NLTX), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical products" industry.

How does Acrivon Therapeutics compare to Organogenesis?

Acrivon Therapeutics (NASDAQ:ACRV) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 10.5% of Acrivon Therapeutics shares are held by insiders. Comparatively, 18.8% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Acrivon Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market. Comparatively, Organogenesis has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

Organogenesis has higher revenue and earnings than Acrivon Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Organogenesis	$564.17M	0.55	$37.03M	-$0.19	N/A

In the previous week, Organogenesis had 2 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 3 mentions for Organogenesis and 1 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 1.87 beat Organogenesis' score of 0.63 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Acrivon Therapeutics	Very Positive
Organogenesis	Positive

Acrivon Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -0.84%. Organogenesis' return on equity of 9.63% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Organogenesis	-0.84%	9.63%	4.76%

Acrivon Therapeutics presently has a consensus target price of $11.67, suggesting a potential upside of 495.24%. Organogenesis has a consensus target price of $5.75, suggesting a potential upside of 139.58%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Acrivon Therapeutics is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Acrivon Therapeutics beats Organogenesis on 8 of the 15 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

In the previous week, Bicycle Therapeutics had 7 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 8 mentions for Bicycle Therapeutics and 1 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 1.87 beat Bicycle Therapeutics' score of -0.29 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Bicycle Therapeutics	Neutral
Acrivon Therapeutics	Very Positive

Acrivon Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. Bicycle Therapeutics' return on equity of -35.74% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
Acrivon Therapeutics	N/A	-64.43%	-57.08%

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 22.0% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Acrivon Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	4.23	-$218.96M	-$3.15	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A

Bicycle Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market.

Bicycle Therapeutics presently has a consensus target price of $14.00, indicating a potential upside of 217.46%. Acrivon Therapeutics has a consensus target price of $11.67, indicating a potential upside of 495.24%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Acrivon Therapeutics beats Bicycle Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Eledon Pharmaceuticals?

Acrivon Therapeutics (NASDAQ:ACRV) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 10.5% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Acrivon Therapeutics and Acrivon Therapeutics both had 1 articles in the media. Eledon Pharmaceuticals' average media sentiment score of 1.89 beat Acrivon Therapeutics' score of 1.87 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Acrivon Therapeutics	Very Positive
Eledon Pharmaceuticals	Very Positive

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A

Acrivon Therapeutics presently has a consensus target price of $11.67, suggesting a potential upside of 495.24%. Eledon Pharmaceuticals has a consensus target price of $9.67, suggesting a potential upside of 151.08%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Acrivon Therapeutics is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Acrivon Therapeutics' return on equity of -64.43% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%

Acrivon Therapeutics has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Summary

Acrivon Therapeutics beats Eledon Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Neoleukin Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Acrivon Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

In the previous week, Acrivon Therapeutics had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for Acrivon Therapeutics and 0 mentions for Neoleukin Therapeutics. Acrivon Therapeutics' average media sentiment score of 1.87 beat Neoleukin Therapeutics' score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Acrivon Therapeutics	Very Positive
Neoleukin Therapeutics	Neutral

Neoleukin Therapeutics' return on equity of -37.22% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Acrivon Therapeutics currently has a consensus price target of $11.67, suggesting a potential upside of 495.24%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Summary

Acrivon Therapeutics beats Neoleukin Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Indaptus Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Acrivon Therapeutics' return on equity of -64.43% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

Acrivon Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 10.5% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Indaptus Therapeutics had 2 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 3 mentions for Indaptus Therapeutics and 1 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 1.87 beat Indaptus Therapeutics' score of 1.44 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Acrivon Therapeutics	Very Positive
Indaptus Therapeutics	Positive

Acrivon Therapeutics presently has a consensus target price of $11.67, suggesting a potential upside of 495.24%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Acrivon Therapeutics is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

Summary

Acrivon Therapeutics beats Indaptus Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Acrivon Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRV vs. The Competition

Export

Metric	Acrivon Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$83.89M	$3.05B	$6.89B	$12.64B
Dividend Yield	N/A	2.06%	2.68%	8.01%
P/E Ratio	-0.98	20.02	27.36	24.52
Price / Sales	N/A	359.27	501.26	84.25
Price / Cash	N/A	56.80	29.24	49.38
Price / Book	0.55	4.29	10.98	6.43
Net Income	-$77.90M	$64.59M	$3.59B	$331.05M
7 Day Performance	10.11%	-1.07%	-0.92%	-1.34%
1 Month Performance	32.43%	4.51%	4.59%	0.52%
1 Year Performance	48.48%	24.67%	29.84%	22.23%

Acrivon Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRV Acrivon Therapeutics	2.4542 of 5 stars	$1.96 flat	$11.67 +495.2%	+48.5%	$83.89M	N/A	N/A	58	Positive News Gap Up
ORGO Organogenesis	1.6324 of 5 stars	$2.48 -0.2%	$5.75 +132.3%	-44.2%	$318.48M	$564.17M	N/A	950
BCYC Bicycle Therapeutics	2.6405 of 5 stars	$4.48 +2.9%	$14.00 +212.8%	-44.9%	$313.17M	$72.86M	N/A	240
ELDN Eledon Pharmaceuticals	2.0685 of 5 stars	$3.99 +0.4%	$9.67 +142.6%	+12.6%	$307.76M	N/A	N/A	10	Positive News Gap Up
NLTX Neoleukin Therapeutics	N/A	$32.56 -7.9%	N/A	+84.9%	$306.00M	N/A	N/A	90	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRV) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. ORGO, BCYC, ELDN, NLTX, and INDP

How does Acrivon Therapeutics compare to Organogenesis?

Summary

How does Acrivon Therapeutics compare to Bicycle Therapeutics?

Summary

How does Acrivon Therapeutics compare to Eledon Pharmaceuticals?

Summary

How does Acrivon Therapeutics compare to Neoleukin Therapeutics?

Summary

How does Acrivon Therapeutics compare to Indaptus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. ORGO, BCYC, ELDN, NLTX, and INDP

How does Acrivon Therapeutics compare to Organogenesis?

Do insiders and institutionals hold more shares of ACRV or ORGO?

Which has more volatility and risk, ACRV or ORGO?

Which has better valuation and earnings, ACRV or ORGO?

Does the media favor ACRV or ORGO?

Is ACRV or ORGO more profitable?

Do analysts prefer ACRV or ORGO?

Summary

How does Acrivon Therapeutics compare to Bicycle Therapeutics?

Does the media favor BCYC or ACRV?

Is BCYC or ACRV more profitable?

Do insiders & institutionals have more ownership in BCYC or ACRV?

Which has higher earnings & valuation, BCYC or ACRV?

Which has more volatility and risk, BCYC or ACRV?

Do analysts recommend BCYC or ACRV?

Summary

How does Acrivon Therapeutics compare to Eledon Pharmaceuticals?

Do institutionals and insiders have more ownership in ACRV or ELDN?

Does the media prefer ACRV or ELDN?

Which has better earnings and valuation, ACRV or ELDN?

Do analysts recommend ACRV or ELDN?

Is ACRV or ELDN more profitable?

Which has more risk & volatility, ACRV or ELDN?

Summary

How does Acrivon Therapeutics compare to Neoleukin Therapeutics?

Which has more volatility & risk, ACRV or NLTX?

Does the media favor ACRV or NLTX?

Is ACRV or NLTX more profitable?

Do institutionals & insiders hold more shares of ACRV or NLTX?

Do analysts recommend ACRV or NLTX?

Which has preferable earnings & valuation, ACRV or NLTX?

Summary

How does Acrivon Therapeutics compare to Indaptus Therapeutics?

Is ACRV or INDP more profitable?

Which has more risk & volatility, ACRV or INDP?

Do insiders & institutionals believe in ACRV or INDP?

Does the media refer more to ACRV or INDP?

Do analysts prefer ACRV or INDP?

Which has better earnings & valuation, ACRV or INDP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools